Estrogen dan Risiko Hipertensi: Mengapa Menopause Menjadi Titik Kritis Kesehatan Vaskular?

Role: Anda adalah Senior Editor dan Pakar pada artikel yang di bahas. Anda memiliki ketajaman analisis teknis, gaya bahasa yang ringkas (compact), profesional, dan modern-formal (Standar Google News & Google Ads). Tugas Utama: Tulis ulang berita dari sumber mentah menjadi artikel profesional dengan format HTML bersih dan desain visual premium. 1. STRUKTUR OUTPUT WAJIB HEADLINE: Buat judul yang berani (Bold), SEO-friendly, dan fokus pada esensi masalah. BACA DALAM 60 DETIK (TL;DR): Buat 3 poin bullet sebagai ringkasan eksekutif. Gunakan diksi yang berbeda dari isi berita (Anti-Redundansi). BODY ARTICLE (HTML): Gunakan struktur di bawah ini. 2. DETAIL DESAIN & INSTRUKSI HTML (VISUAL GUIDELINES) Kemas isi artikel di dalam tag

dengan spesifikasi gaya visual sebagai berikut: Label Kategori: Gunakan . Desain: Teks merah bold, uppercase, font-size kecil (12-14px), dengan border-left: 4px solid #dc2626 dan padding-left: 10px. Lead Paragraf: Gunakan

. Desain: Font-size lebih besar (1.2em - 1.3em), bold/semi-bold (font-weight: 700), warna gelap (#1a1a1a). Harus merangkum 5W+1H secara lugas. Paragraf Isi: Gunakan tag

. Desain: Teks rata kanan-kiri (justify), line-height: 1.8, warna abu gelap (#333). Hubungkan fakta dengan tren industri atau kebijakan. Kotak Info (Conflict-Box): Gunakan

. Desain: Background abu sangat muda (#fafafa), border tipis (#e2e8f0), border-top: 6px solid #dc2626 (Warna Merah) atau #0047ab (Warna Biru tergantung urgensi), padding 25px, radius 8px. Berisi poin-poin "Data Kunci" atau "Penyebab Utama". Quote/Highlight: Gunakan

. Desain: Background merah sangat muda (#fef2f2), border-left: 5px solid #dc2626, font-style: italic, padding: 15px 25px. Pertimbangkan jika harus menggunakan table, jika iya maka . Tabel Komparasi: Gunakan tag . Desain: Lebar 100%, border-collapse, header (

) berwarna abu-abu muda (#f8f9fa) dengan border tipis. Closing: Paragraf terakhir harus bersifat forward-looking (pandangan masa depan). 3. INSTRUKSI REDAKSIAL (STRICT RULES) Originalitas: Parafrase total (Plagiarisme < 10%). Kembangkan inti sari menjadi 1000 kata yang berbobot. Netralitas: Gunakan kata kerja objektif (menyoroti, menilai, memproyeksikan). Anti-Promosi: Dilarang keras menyebut "LyndNews", "Lyndhub", atau "Ketajaman analisis". Hashtag: Sertakan 5-7 hashtag relevan di akhir (Tanpa #Lyndnews). [JUDUL]: How might estrogen affect hypertension risk at menopause? According to the U.S. Department of Health and Human Services’ Office on Women’s Health, it’s not uncommon for women ages 40 to 59 years oldTrusted Source to experience high blood pressure (hypertension) as they transition into menopause, a period also known as perimenopause. Additionally, past research shows that about 41% of women develop hypertension when transitioning out of menopause, known as postmenopause. There are several factors that play a role in raising high blood pressure risk during perimenopause and postmenopause, including a decrease in levels of the hormone estrogen. This can lead to stiffening of the arteries and increase the body’s sensitivity to salt. On the flipside, past research shows that premenopausal women usually have a lower high blood pressure risk than perimenopausal or postmenopausal women, partly because they have higher levels of estrogen in their bodies. Now a new study published in the journal Mathematical Biosciences helps to explain just how estrogen may help protect against hypertension. How estrogen’s vasodilation abilities may help lower blood pressure For this study, researchers developed a mathematical model of women’s cardiovascular and kidney systems. The model was used to incorporate the effects of estrogen on the body’s renin-angiotensin systemTrusted Source, which is a hormone system that helps regulate electrolyte balance, blood volume, and blood pressure. Through their model, scientists discovered that estrogen’s ability to relax and widen blood vessels, known as vasodilation, may be the key factor behind its ability to help lower blood pressure. Researchers also used their model to predict how two common anti-hypertensive drugs might work with estrogen. They found that angiotensin receptor blockers (ARBs) may be more effective than angiotensin converting enzyme (ACE) inhibitors in treating high blood pressure in women, even after their estrogen levels have declined postmenopause. “Estrogen is often thought of only in terms of reproductive health, but it plays a much broader role in how the body functions,” said Anita Layton, PhD, the Canada 150 Research Chair Laureate in Mathematical Biology and Medicine and professor of applied mathematics, computer science, pharmacy, and biology at the University of Waterloo, and lead author of this study, in a press release. “It affects how blood vessels respond, how the kidneys regulate fluids, and how different systems communicate with one another. What we found is that its impact on blood vessels is especially important for regulating blood pressure,” Layton explained. “For too long, women’s health, especially older women’s health, has been overlooked by medicine,” she added. “Understanding how age and sex affect the body and, therefore, treatment, is an equity issue.” Hormone therapy may be key to lowering cardiovascular risks Medical News Today had the opportunity to speak with Prudence Hall, MD, an OB/GYN in private practice in Santa Monica, CA, about this study. Hall, who was not involved in the research, commented that her first reaction to its findings was relief that once again, a study has addressed the issue of age-related increases in cardiovascular diseaseTrusted Source and blood pressure, specifically in menopausal women. “Menopausal increases in blood pressure contributes tremendously to morbidity and mortality in menopausal women, with cardiovascular disease being the number one cause of death in womenTrusted Source,” added Hall, noting that treating hypertension could help to significantly reduce early death risk in women. “We simply have to address menopausal hormonal deficiencies and replace those missing hormones with transdermal estradiol, which is bioidentical to every woman’s estrogen,” she suggested. More research on the health role of estrogen needed MNT also spoke with G. Thomas Ruiz, MD, a board-certified OB/GYN at MemorialCare Orange Coast Medical Center in Fountain Valley, CA, likewise not involved in this research. Ruiz commented that this is yet another one of the published studies over the past 2 to 3 years that suggest there may be significant benefits when it comes to estrogen therapy for menopause. “Researchers need to continue to look at the various organs within a woman’s body that have estrogen receptors to understand estrogen’s positive effects,” Ruiz explained. “As long as a menopausal woman takes estrogen, those receptors will function,“ he theorized. According to Ruiz: “If a postmenopausal woman is not taking estrogen, eventually those estrogen receptors will be downregulated and become nonfunctional. Some research on how hormone replacement therapy affects a woman’s metabolism and metabolic rate would be useful.” The key question, he said, is: “Everyone’s metabolism slows with aging but if a woman is on hormone replacement therapy, what is the rate of metabolism slowing as compared to a woman not taking hormone replacement therapy?” For more insight into the cardiovascular impact examined by study, MNT spoke to Cheng-Han Chen, MD, a board-certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA. “This mathematical model suggests that estrogen contributes to cardiovascular health by helping to relax blood vessels, thereby improving blood pressure,” Chen, who was also not involved in this study, said. “These results add to our continuously evolving understanding of how estrogen affects our heart health.” “High blood pressure is a significant risk factor for developing heart disease,” he continued. “As postmenopausal women are at higher risk for heart disease, controlling blood pressure in this population is important to help improve their heart health. Future research will be necessary to validate these findings in a biological model.” Recent surveys show that about 12% of Americans are currently taking a glucagon-like peptide-1 (GLP-1) receptor agonistTrusted Source medication, with as many as 35% of U.S. citizens interested in using them. With such an increased interest in these medications — including Ozempic, Zepbound, Mounjaro, and Wegovy — researchers have been examining other potential health benefits of these drugs outside of type 2 diabetes management and weight loss. For example, studies have been looking at the use of GLP-1s for reducing the risk of cardiovascular disease and chronic kidney disease, treatment of nonalcoholic fatty liver disease and obstructive sleep apneaTrusted Source, and even potential protection against dementia. Now, two new studies recently presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) offer insights on how GLP-1 medications might influence musculoskeletal health, both positively and negatively. Their results are yet to appear in a peer-reviewed journal. How might GLP-1 use impact orthopedic surgeries? One study looked at what type of impact GLP-1 use might have on people undergoing 10 of the most common orthopedic surgeries, including total hip arthroplasty (THA), total knee arthroplasty (TKA), carpal tunnel release, and lumbar fusion. “GLP-1 medications are now widely used for diabetes and weight management, and their use is expanding rapidly,” Haroun Haque, MS, a third-year medical student at SUNY Downstate College of Medicine and lead investigator of this study, told Medical News Today. “Because they affect metabolism, inflammation, cardiovascular health, and metabolic function overall, it is important to understand how they influence surgical recovery and musculoskeletal health. As more patients take these medications, surgeons need evidence to guide safe and effective perioperative care,” said Haque. “We focused on the 10 most common orthopedic procedures because they represent a large portion of musculoskeletal surgical care in the United States,” he continued. “These surgeries frequently involve patients with obesity and metabolic disease, who are most likely to be prescribed GLP-1 medications.” GLP-1s linked to lower risk for postoperative ER visits At the study’s conclusion, researchers found that use of GLP-1 and semaglutide was correlated with significantly lower chances for postoperative emergency department visits, without an increased surgical risk. “Emergency department visits after surgery are an important indicator of complications and healthcare utilization,” Haque explained. “The association between GLP-1 use and lower emergency department visits suggests these medications may be linked to improved short-term recovery. Importantly, we did not observe evidence of increased surgical risk, which is reassuring given concerns about perioperative management.” Additionally, scientists discovered the use of GLP-1s was also linked to significantly lower surgical site infection rates among patients undergoing TKA and THA. “Infections after total knee and total hip arthroplasty are serious and costly complications,” Haque said. “Seeing lower infection rates in GLP-1 users raises the possibility that improved metabolic control and reduced inflammation may positively influence surgical outcomes. Even small reductions in infection risk could have meaningful clinical impact.” “GLP-1 medication use among orthopedic patients is increasing rapidly and is projected to continue rising,” he continued. “Our findings suggest these medications may be linked to improved short-term postoperative outcomes; however we cannot establish causality based on these retrospective results and further prospective investigations are needed.” GLP-1s may increase osteoporosis risk in diabetes, obesity In the second study, researchers focused on examining how GLP-1 use might impact the risk of developing osteoporosis, gout, or osteomalacia (bone softening) in people with type 2 diabetes and obesity. Scientists analyzed electronic medical records for more than 73,000 people and found that after 5 years, GLP-1 use was linked to a significantly higher risk of developing osteoporosis, compared to those not taking the medication. Researchers also found a higher incidence of gout among GLP-1 users, and the greatest relative risk increase was seen for osteomalacia. “We are just now reaching the precipice where 5- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” sayid Muaaz Wajahath, a fourth-year medical student at Michigan State University College of Human Medicine and primary investigator of this study in a press release. “Any medication that sees this rapid adoption warrants close examination, particularly in orthopedics where obesity and surgical intervention often overlap, and when the long-term effects of GLP-1 RA exposure on bone and joint health remain poorly understood,” Wajahath detailed. “Whenever you have a patient who is prone to osteoporosis, gout, or osteomalacia, clinicians should consider bone health surveillance and monitor for delayed-onset complications in at-risk populations,” he added. “These changes can be implemented immediately and can be an easy fix to potentially prevent these side effects,” said Wajahath. Why might GLP-1 use cause higher osteoporosis risk? MNT had the opportunity to speak with Laurie Glasser, MD, a physical medicine and rehabilitation physician at Hackensack Meridian Health’s Jersey Shore University Medical Center in New Jersey, as to why GLP-1 use might be linked to a higher risk for osteoporosis, gout, and osteomalacia in people with type 2 diabetes and obesity. According to Glasser, who was not involved in these studies: “There have been some reports of decreased bone mineral density (BMD)Trusted Source associated with weight loss, but the reduction in BMD appears similar to that seen with other weight-loss interventions and does not translate into an increased fracture risk. In addition, meta-analysesTrusted Source suggest that GLP-1 RAs may actually improve bone density in the lumbar spine and hip compared with controls.” “Any rapid weight loss, including from calorie restriction or bariatric surgery, is likely to be associated with some bone loss, so I do not think blaming GLP-1s is the answer,” she added. “ GLP-1s are extremely helpful drugs for my patients and, when used responsibly, have contributed to many positive outcomes.” Confirming improved orthopedic outcomes with GLP-1 use MNT also spoke with Bert Mandelbaum, MD, sports medicine specialist, orthopedic surgeon and co-director of the Regenerative Orthobiologic Center at Cedars-Sinai Orthopaedics in Los Angeles. In regards to the study looking at GLP-1 use and orthopedic procedure postoperative risk, Mandelbaum, who was likewise not involved in the recent studies, said that these results confirm that doctors are seeing a lot more use of GLP-1 agonists, and in the orthopedic surgical group that they’re basically improving outcomes overall. “Patient reported outcome scores seem to be better, revision rates are decreased, at least in this population study,” he continued. “So, what can we conclude from that? It’s going to take us a while to really sort out the specificity of everything, but at least the initial studies are showing that there’s benefits to the GLP-1 agonist.” “That there are […] direct benefitsTrusted Source, specifically affecting orthopedic and musculoskeletal issues, that affect bone, cartilage, muscle, and fat, changing body composition in a very direct way,” Mandelbaum explained. “And as a consequence, there’s less BMI. And also there’s a direct effect on the cells, the chondrocyteTrusted Source. And they figured out the pathway, that it works through the AMPK pathway that has a direct positive effect on the mitochondria and oxidative processes that are to the positive. So it keeps the chondrocyte, which is the cell that preserves cartilage and minimizes the progression of arthritis, and therefore makes its function better.” – Bert Mandelbaum, MD Share: Lanjutkan membaca Kalkulator Tidur: Panduan Ilmiah Menentukan Durasi Istirahat Ideal Berdasarkan UsiaPanduan Lengkap Layanan dan Produk Kesehatan Mental: Dari Terapi Online hingga MeditasiPanduan Pemeriksaan Payudara Sendiri: Langkah Deteksi Dini yang Perlu Diketahui Sumber dari : medicalnewstoday.com